Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA, ADHERE Study Group

Open source

DOI: 10.1016/s1474-4422(24)00309-0
Published: 2024 Oct
Container: The Lancet. Neurology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-24-00309-0,
  title = {Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.},
  author = {Allen JA and Lin J and Basta I and Dysgaard T and Eggers C and Guptill JT and Gwathmey KG and Hewamadduma C and Hofman E and Hussain YM and Kuwabara S and Le Masson G and Leypoldt F and Chang T and Lipowska M and Lowe M and Lauria G and Querol L and Simu MA and Suresh N and Tse A and Ulrichts P and Van Hoorick B and Yamasaki R and Lewis RA and van Doorn PA and ADHERE Study Group},
  year = {2024},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(24)00309-0},
  url = {https://doi.org/10.1016/s1474-4422(24)00309-0}
}

RIS

TY  - JOUR
TI  - Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
AU  - Allen JA
AU  - Lin J
AU  - Basta I
AU  - Dysgaard T
AU  - Eggers C
AU  - Guptill JT
AU  - Gwathmey KG
AU  - Hewamadduma C
AU  - Hofman E
AU  - Hussain YM
AU  - Kuwabara S
AU  - Le Masson G
AU  - Leypoldt F
AU  - Chang T
AU  - Lipowska M
AU  - Lowe M
AU  - Lauria G
AU  - Querol L
AU  - Simu MA
AU  - Suresh N
AU  - Tse A
AU  - Ulrichts P
AU  - Van Hoorick B
AU  - Yamasaki R
AU  - Lewis RA
AU  - van Doorn PA
AU  - ADHERE Study Group
PY  - 2024
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(24)00309-0
UR  - https://doi.org/10.1016/s1474-4422(24)00309-0
ER  -

APA

JA, A., J, L., I, B., T, D., C, E., JT, G., KG, G., C, H., E, H., YM, H., S, K., G, L. M., F, L., T, C., M, L., M, L., G, L., L, Q., MA, S., N, S., A, T., P, U., B, V. H., R, Y., RA, L., PA, V. D., & Group, A. S. (2024). Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(24)00309-0

Source records

pubmed · retrieved 2026-09-26T16:00:37.788Z
europe-pmc · retrieved 2026-09-26T16:00:37.812Z
hal · retrieved 2026-09-26T16:00:37.814Z